alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.6300 Implantable radiofrequency transponder system for patient identification and health information. ( a ) *Identification.* An implantable radiofrequency transponder system for patient identification and health information is a device intended to enable access to secure patient identification and corresponding health information. This system may include a passive implanted transponder, inserter, and scanner. The implanted transponder is used only to store a unique electronic identification code that is read by the scanner. The identification code is used to access patient identity and corresponding health information stored in a database.
( b ) *Classification.* Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Implantable Radiofrequency Transponder System for Patient Identification and Health Information.” See § 880.1(e) for the availability of this guidance document. This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 880.9.
[69 FR 71704, Dec. 10, 2004]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

                    The purpose of this notice is to inform the public about a meeting of the NIH Blue Ribbon Panel To Advise on the Risk Assessment of the National Emerging Infectious Diseases Laboratories at Boston University                           ( print page 10294)                        Medical Center. The meeting will be held on Friday, March 19, 2010, at the National Institutes of Health, Building 31, 31 Center Drive, Floor 6C, Room 6, Bethesda, MD 20892, from approximately 8:30 a.m. to 2 p.m.                

This meeting is the second in a series of public meetings with the National Research Council to review the ongoing supplementary risk assessment study. It was originally scheduled to take place on February 12, 2010, but had to be postponed due to extreme weather conditions on the East Coast.

Signup for public comment will begin at approximately 8 a.m. In the event that time does not allow for all those interested in presenting oral comments, anyone may file written comments using the following address below.

                    An agenda and slides for the meeting may be obtained prior to the meeting by connecting to                     *http://nihblueribbonpanel-bumc-neidl.od.nih.gov/​*. For additional information concerning this meeting, please contact Ms. Laurie Lewallen, Advisory Committee Coordinator, Office of Biotechnology Activities, Office of Science Policy, Office of the Director, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892-7985; telephone 301-496-9838; e-mail                     *lewallenl@od.nih.gov*.                

Dated: March 1, 2010.

Amy P. Patterson,

Director, Office of Biotechnology Activities, National Institutes of Health.

[FR Doc. 2010-4724 Filed 3-4-10; 8:45 am]

BILLING CODE 4140-01-P
EXHIBIT 32.b



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of American Affordable Housing II Limited Partnership (the "Partnership") on Form 10-Q for the period ended September 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Marc N. Teal, Principal Financial Officer of the general partner of the general partner of the Partnership's general partner, C&M Management Inc., certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge, after due inquiry:



|(1) | The Report fully complies with the requirements of section 13(a)-15 or 15(d)-15 of the Securities and Exchange Act of 1934; and                         
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                         
|(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Partnership.



|                  |     |                            
|----------------- | --- | ---------------------------
|Date:             |     |                            
|November 16, 2009 | By: | /s/ Marc N. Teal           
|                  |     |                            
|                  |     | Marc N. Teal               
|                  |     | Principal Financial Officer

A signed original of this written statement required by Section 906, or other

document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Fund and will be retained by the Fund and furnished to the Securities and Exchange Commission or its staff upon request.
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 04-8028

CALVIN R. MALLORY,

Petitioner - Appellant,

versus

A. T. ROBINSON, Supt.; POWHATAN CORRECTIONAL

CENTER,

Respondents - Appellees.

Appeal from the United States District Court for the Eastern

District of Virginia, at Richmond. James R. Spencer, Chief

District Judge. (CA-04-829-3)

Submitted: April 28, 2005 Decided: May 5, 2005

Before WILLIAMS, KING, and DUNCAN, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Calvin R. Mallory, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
- 2 -

PER CURIAM:

Calvin R. Mallory seeks to appeal the district court’s

order denying relief on his petition filed under 28 U.S.C. § 2254

(2000). The district court dismissed the petition without

prejudice because the action was not filed on the proper form in

violation of the court’s October 4, 2002, pre-filing injunction.

The order is not appealable unless a circuit justice or judge

issues a certificate of appealability. 28 U.S.C. § 2253(c)(1)

(2000). A certificate of appealability will not issue absent “a

substantial showing of the denial of a constitutional right.” 28

U.S.C. § 2253(c)(2) (2000). A prisoner satisfies this standard by

demonstrating that reasonable jurists would find that his

constitutional claims are debatable and that any dispositive

procedural rulings by the district court are also debatable or

wrong. See Miller-El v. Cockrell, 537 U.S. 322, 336-38 (2003);

Slack v. McDaniel, 529 U.S. 473, 484 (2000); Rose v. Lee, 252 F.3d

676, 683 (4th Cir. 2001). We have independently reviewed the

record and conclude that Mallory has not made the requisite

showing. Accordingly, we deny Mallory’s motions to proceed in

forma pauperis, for “production of documents,” and appointment of

counsel, deny a certificate of appealability, and dismiss the

appeal. We dispense with oral argument because the facts and legal

contentions are adequately presented in the materials before the

court and argument would not aid the decisional process. 

DISMISSED
Exhibit 32.1

Certification Pursuant to 18 U.S.C. § 1350 as Adopted

Pursuant to § 906 of the
Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, in
connection with the filing of the Form 10-Q of STERIS Corporation (the Company) for the quarter ended December 31, 2007, as filed with the Securities and Exchange Commission on the date hereof (the Report), each of the
undersigned officers of the Company certifies, that, to such officers knowledge:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the
periods expressed in the Report.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



/s/    WALTER M ROSEBROUGH,
JR.Name:

Walter M Rosebrough, Jr.Title:

President and Chief Executive Officer/s/    MICHAEL J. TOKICHName:

Michael J. TokichTitle:

Senior Vice President and Chief Financial Officer


Dated: February 6, 2009
# C_2015311EN.01006104.xml

| 21.9.2015 | EN | Official Journal of the European Union | C 311/61 |
| --- | --- | --- | --- |

21.9.2015

EN

Official Journal of the European Union

C 311/61

---

Order of the General Court of 30 June 2015 — PAN Europe and Unaapi v Commission

(Case T-729/14) (1)

1

(2015/C 311/70)

Language of the case: English

The President of the Seventh Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 7, 12.1.2015.

1

---
Exhibit 23.1

CONSENT OF INDEPENDENT AUDITORS

Audit
Committee of the Board of Directors and Stockholders
First Mariner Bancorp
Baltimore, Maryland

We
consent to the incorporation by reference in the Registration Statements (Nos. 333-60961, 333-60963 and 333-60967) on Form S-8 and (No. 333-67854) on Form S-2 of
First Mariner Bancorp and subsidiary (First Mariner) of our report dated February 14, 2003, relating to the consolidated statements of financial condition of First Mariner as of
December 31, 2002 and 2001, and the related consolidated statements of operations, changes in stockholders' equity and cash flows for each of the three years in the period ended
December 31, 2002, which report appears in the December 31, 2002 annual report on Form 10-K of First Mariner.



Baltimore,
Maryland
March 28, 2003

---

QuickLinks
# C_2015213EN.01003501.xml

| 29.6.2015 | EN | Official Journal of the European Union | C 213/35 |
| --- | --- | --- | --- |

29.6.2015

EN

Official Journal of the European Union

C 213/35

---

Judgment of the General Court of 13 May 2015 — Deutsche Post v OHIM — PostNL Holding (TPG POST)

(Case T-102/14) (1)

1

((Community trade mark - Opposition proceedings - Application for Community word mark TPG POST - Earlier national and Community word marks POST and Deutsche Post - Relative ground for refusal - No likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009))

(2015/C 213/58)

Language of the case: German

Parties

Parties

Applicant: Deutsche Post AG (Bonn, Germany) (represented by: K. Hamacher and C. Giersdorf, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: G. Schneider and S. Hanne, Agents)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM: PostNL Holding BV (The Hague, Netherlands)

Other party to the proceedings before the Board of Appeal of OHIM:

Re:

Re:

Action brought against the decision of the First Board of Appeal of OHIM of 11 December 2013 (Case R 2108/2012-1), relating to opposition proceedings between PostNL Holding BV and Deutsche Post AG.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the application. |
| --- | --- |

1.

Dismisses the application.

| 2. | Orders Deutsche Post AG to pay the costs. |
| --- | --- |

2.

Orders Deutsche Post AG to pay the costs.

---

(1)  OJ C 112, 14.4.2014.

1

---
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1090 Angiotensin converting enzyme (A.C.E.) test system. ( a ) *Identification.* An angiotensin converting enzyme (A.C.E.) test system is a device intended to measure the activity of angiotensin converting enzyme in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of diseases such as sarcoidosis, a disease characterized by the formation of nodules in the lungs, bones, and skin, and Gaucher's disease, a hereditary disorder affecting the spleen.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 84 FR 71796, Dec. 30, 2019]






Junior Ranger Pledge

Date__________

As a Junior Ranger, I pledge to preserve and protect Fort Washington Park. 

I will learn more about the War of 1812, the Civil War, American History, and 

Nature. When I return home to ____________________,I will share what 

I learned with others. In the future, I will work to protect the parks, our history, 

and the environment. Through my actions, future generations may enjoy them like 

I have. X________________________ 

(Hometown)

(Name)



























S N Y F K P C M A L T P W M M G E U N Y

J H A S K I N S C N B Y A F O O G S S L

B S O S Z U G T Y R E U S S H X N Q B L

Y E E A F I F H P Q F S H F D Z N R N Q

M G N I E B A R N A R D I X B D R I O W

W G E M D D A Y X T U W N H J J L Z T E

I I M S S E E U N S L M G D Y S O N E D

L D W L Y D C M C A B R T H P S E V A Q

K O B M E Z X A O N M A O J G N G E R W

I N P G R N F Q T R K S N W D F T M O J

N O Q W H S F R U U Y G E I H S Y K D J

S M M K P J S A Y A R R C M I I J L M I

Y E S W M N E Q N K F O M M A S T S A R

C F Z L U P Z D W T T Z R A D J P E N J

W V P Z H M S T F T S A C I F J I E E L


Certificate of Completion

This certifies that __________________________________________________ is awarded the title of 

Fort Washington Park Junior Ranger

Park Ranger Date

Fort Washington passport stamp
SERVED: OCTOBER28, 2014 U.S. DEPARTMENT OF TRANSPORTATION OFFICE OF HEARINGS

WASHINGTON, DC IN THE MATTER OF JOHNNYPL DOCKETNO. FAA-2014-0808 (Civil Penalty Action) NOTICE OF ASSIGNMENT OF PROCEEDING }**~--:** ... ""-

This proceeding (heretofore designated as Case No. 2010WP250060) has been assigned to Administrative LawJudge Richard C. Goodwin. All future pleadings and other communications regarding this proceeding shall be served onthe Judge, the FAAHearing Docket, andthe other persons onthe attached Service List.

Attachment
- Service List 

# M--'L-Q
Ronnie A. Yoder ChiefAdministrative LaSERVICE LIST - BY U.S. MAIL ORIGINAL & ONE COPY Federal Aviation Administration 800 Independence Avenue, S.W. Washington, DC 20591 Attention: Hearing Docket Clerk, AGC-430 Wilbur Wright Building-Suite 2W1000 1

JohnNypl, Respondent 16325 State Hwy. 49 Grass Valley, CA 95949-9118 ONE COPY

Lindsay M. Nakamura, Complainant's Counsel Office ofthe Regional Counsel, APW-7.11 Federal Aviation Administration Western-Pacific Region P.O. Box 92007 Los Angeles, CA 90009-2007 TEL: 310-725-7138 FAX: 310-725-6816 The Honorable Richard C. Goodwin,Administrative LawJudge Office ofHearings, M-20 U.S. Department ofTransportation 1200 New Jersey Avenue, S.E. (E11-310) Washington, DC 20590 TEL: 202-366-5121 StaffAssistant FAX: 202-366-7536 DocketNo. FAA-2014-0808 (Civil Penalty Action)

1 Service was byU.S. Mail. For service in person or by expedited courier, use the following address: Federal Aviation Administration, 600 Independence Avenue, S.W., Wilbur Wright Building-Suite 2Wl000, Washington, DC 20591; Attention: Hearing Docket Clerk, AGC-430. 2
# C_2015007EN.01004201.xml

| 12.1.2015 | EN | Official Journal of the European Union | C 7/42 |
| --- | --- | --- | --- |

12.1.2015

EN

Official Journal of the European Union

C 7/42

---

Action brought on 24 October 2014 — Prominvestbank v Council

(Case T-739/14)

(2015/C 007/47)

Language of the case: Spanish

Parties

Parties

Applicant: Prominvestbank (Kiev, Ukraine) (represented by: J. Viñals Camallonga and J. Iriate Ángel, lawyers)

Applicant:

Defendant: Council of the European Union

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul Article 1 of Council Decision 2014/512/CFSP of 31 July 2014 in so far as it concerns the applicant and declare that the restrictive measures imposed by that provision do not apply to it; |
| --- | --- |

—

annul Article 1 of Council Decision 2014/512/CFSP of 31 July 2014 in so far as it concerns the applicant and declare that the restrictive measures imposed by that provision do not apply to it;

| — | annul Article 5 of Council Regulation (EU) No 833/2014 of 31 July 2014 in so far as it concerns the applicant and declare that the restrictive measures imposed by that provision do not apply to it; |
| --- | --- |

—

annul Article 5 of Council Regulation (EU) No 833/2014 of 31 July 2014 in so far as it concerns the applicant and declare that the restrictive measures imposed by that provision do not apply to it;

| — | annul replacement Article 1 provided for by Council Decision 2014/659/CFSP of 8 September 2014 in so far as it concerns the applicant and declare that the restrictive measures imposed by that provision do not apply to it; |
| --- | --- |

—

annul replacement Article 1 provided for by Council Decision 2014/659/CFSP of 8 September 2014 in so far as it concerns the applicant and declare that the restrictive measures imposed by that provision do not apply to it;

| — | annul replacement Article 5 provided for by Council Regulation No 960/2014 of 8 September 2014 in so far as it concerns the applicant and declare that the restrictive measures imposed by that provision do not apply to it; |
| --- | --- |

—

annul replacement Article 5 provided for by Council Regulation No 960/2014 of 8 September 2014 in so far as it concerns the applicant and declare that the restrictive measures imposed by that provision do not apply to it;

| — | order the Council of the European Union to pay the costs. |
| --- | --- |

—

order the Council of the European Union to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

The pleas in law and main arguments are the same as those already put forward in Case T-737/14 (Vnesheconombank v Council).

Vnesheconombank

Council

---
Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ViroPharma Incorporated (the Company) on Form
10-K for the period ending December 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the Report), each of the undersigned officers of the Company, certify, pursuant to 18 U.S.C. § 1350, as
adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                                                                              
|------------------------------------------------------------------------------
|                                                                              
|/s/    MICHEL DE
ROSEN                                                        
|Michel de Rosen                                                               
|President, Chief Executive Officer and Chairman of the Board of Directors     
|                                                                              
|February 27, 2007                                                             
|                                                                              
|/s/    VINCENT J. MILANO                                                      
|Vincent J. Milano                                                             
|Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer
|                                                                              
|February 27, 2007
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.5275 Nerve cuff. ( a ) *Identification.* A nerve cuff is a tubular silicone rubber sheath used to encase a nerve for aid in repairing the nerve (e.g., to prevent ingrowth of scar tissue) and for capping the end of the nerve to prevent the formation of neuroma (tumors).
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.3350 Hip joint metal/polymer semi-constrained cemented prosthesis. ( a ) *Identification.* A hip joint metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and an acetabular resurfacing component made of ultra-high molecular weight polyethylene and is limited to those prostheses intended for use with bone cement (§ 888.3027).
( b ) *Classification.* Class II.